Healthcare Industry News: GSK
News Release - June 2, 2008
Adolor Promotes Dr. Lee Techner to Vice President, Medical Affairs and Medical DirectorEXTON, Pa.--(HSMN NewsFeed)--Adolor Corporation (Nasdaq:ADLR ) announced today the promotion of Lee Techner, D.P.M. to vice president, medical affairs and medical director effective immediately. Dr. Techner will report directly to Eliseo Oreste Salinas, M.D., MSc, senior vice president, research and development and chief medical officer, Adolor Corporation.
“Lee’s contributions to the success of the clinical development program for Entereg® have been substantial,” said Michael Dougherty, president and chief executive officer, Adolor Corporation. “His expertise and experience will be invaluable in leading further clinical evaluation of Entereg and directing our medical affairs activities.”
Dr. Techner joined Adolor in March 2001 as a director, clinical research. In January 2004, he was promoted to senior medical director, clinical research and development, during which time he served as a key contributor to the development of Adolor’s first FDA-approved drug, Entereg. In 2007, Dr. Techner also assumed responsibility for Adolor’s Medical Affairs functions. Prior to 2001, Dr. Techner worked for Omnicare Clinical Research as a medical director.
Dr. Techner has conducted primary research in the areas of pulmonary medicine, rheumatology and foot and ankle surgery in hospitals throughout the Northeast and has published work in the professional journals Surgery and the Journal of the American College of Surgeons, among others. Dr. Techner earned a Doctor of Podiatric Medicine degree from the California College of Podiatric Medicine in San Francisco, CA. Dr. Techner was in private practice for over 15 years and a Fellow, American College of Foot and Ankle Surgeons.
About Adolor Corporation
Adolor Corporation (Nasdaq:ADLR ) is a biopharmaceutical company specializing in the discovery, development and commercialization of novel prescription pain management products. By applying its knowledge and expertise in pain management, along with ingenuity, Adolor is seeking to make a positive difference for patients, caregivers and the medical community. For more information, visit www.adolor.com.
This release, and oral statements made with respect to information contained in this release, may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Such known risks and uncertainties relate to, among other factors: the risk that Entereg may not be a commercial success; the uncertainty of market acceptance of Entereg, including acceptance by hospitals, physicians, payors or the medical community; the risk that the Risk Evaluation and Mitigation Strategy or REMS, including the registration of hospitals could materially adversely affect the commercial prospects for ENTEREG or negatively impact the uptake of Entereg, the risks associated with government regulations relating to marketing and selling pharmaceutical products; the risk of product liability claims; the risks of reliance on third party manufacturers; the risk of competitive products; the risk that the alvimopan Investigational New Drug Application (IND) for OBD remain on clinical hold indefinitely; the risk that Entereg may not be approved in OBD or any indication other than the FDA approved indication in bowel resection surgery; the risk that filing targets for regulatory submissions are not met; the risk that the results of other clinical trials of Adolor's drug products and drug product candidates, including ENTEREG, are not positive or do not support safety or efficacy; the costs, delays and uncertainties inherent in scientific research, drug development, clinical trials and the regulatory approval process; the changing regulatory environment; risks associated with intellectual property protection for Adolor’s products and third party intellectual property; Adolor's history of operating losses since inception and its need for additional funds to operate its business; Adolor's reliance on its collaborators, including GSK, in connection with the development and commercialization of ENTEREG; market acceptance of Adolor's products, if regulatory approval is achieved; competition; and securities litigation.
Further information about these and other relevant risks and uncertainties may be found in Adolor's Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Adolor urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Adolor at http://www.adolor.com. Given the uncertainties affecting pharmaceutical companies in the development stage, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Adolor undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.